Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Schiestl

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Biologicals : Journal of the International Association of Biological Standardization|July 26, 2011
A biosimilar industry view on the implementation of the WHO guidelines on evaluating similar biotherapeutic productsMartin Schiestl
ESMO Open|October 27, 2017
The ESMO position paper on biosimilars in oncology: enhancing the provision of accurate education and informationMartin Schiestl, Andriy Krendyukov
ESMO Open|April 13, 2018
Extrapolation concept at work with biosimilar: a decade of experience in oncologyAndriy Krendyukov, Martin Schiestl
Critical Reviews in Oncology/Hematology|August 14, 2019
Biosimilars in oncology: A decade of experience with granulocyte colony-stimulating factor and its implications for monoclonal antibodiesAndriy Krendyukov, Martin Schiestl
Drug Design, Development and Therapy|May 30, 2017
Ten years of biosimilars in Europe: development and evolution of the regulatory pathwaysMartin Schiestl, Markus Zabransky, Fritz Sörgel
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 9, 2018
Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience GainedMatti Aapro, Andriy Krendyukov, Martin Schiestl, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 2, 2018
Correction to: Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience GainedMatti Aapro, Andriy Krendyukov, Martin Schiestl, et al.
Clinical Drug Investigation|March 4, 2018
Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?David Goldsmith, Frank Dellanna, Martin Schiestl, et al.
The AAPS Journal|November 29, 2018
The Assessment of Quality Attributes for Biosimilars: a Statistical Perspective on Current Practice and a ProposalJohanna Mielke, Franz Innerbichler, Martin Schiestl, et al.
Nature Biotechnology|April 12, 2011
Acceptable changes in quality attributes of glycosylated biopharmaceuticalsMartin Schiestl, Thomas Stangler, Claudia Torella, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Biologicals : Journal of the International Association of Biological Standardization|July 26, 2011
A biosimilar industry view on the implementation of the WHO guidelines on evaluating similar biotherapeutic productsMartin Schiestl
ESMO Open|October 27, 2017
The ESMO position paper on biosimilars in oncology: enhancing the provision of accurate education and informationMartin Schiestl, Andriy Krendyukov
ESMO Open|April 13, 2018
Extrapolation concept at work with biosimilar: a decade of experience in oncologyAndriy Krendyukov, Martin Schiestl
Critical Reviews in Oncology/Hematology|August 14, 2019
Biosimilars in oncology: A decade of experience with granulocyte colony-stimulating factor and its implications for monoclonal antibodiesAndriy Krendyukov, Martin Schiestl
Drug Design, Development and Therapy|May 30, 2017
Ten years of biosimilars in Europe: development and evolution of the regulatory pathwaysMartin Schiestl, Markus Zabransky, Fritz Sörgel
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|February 9, 2018
Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience GainedMatti Aapro, Andriy Krendyukov, Martin Schiestl, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 2, 2018
Correction to: Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience GainedMatti Aapro, Andriy Krendyukov, Martin Schiestl, et al.
Clinical Drug Investigation|March 4, 2018
Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?David Goldsmith, Frank Dellanna, Martin Schiestl, et al.
The AAPS Journal|November 29, 2018
The Assessment of Quality Attributes for Biosimilars: a Statistical Perspective on Current Practice and a ProposalJohanna Mielke, Franz Innerbichler, Martin Schiestl, et al.
Nature Biotechnology|April 12, 2011
Acceptable changes in quality attributes of glycosylated biopharmaceuticalsMartin Schiestl, Thomas Stangler, Claudia Torella, et al.
Pageof 2